· SciBase's PMA application was accepted on January 14th as completestarting the formal evaluation process by the FDA. There has been ahigh level of interaction between SciBase and the FDA during andcontinuing after the first quarter.

· Continued good growth in key market Germany with total sales up20% and electrode sales volume up 49%.

· SciBase has signed a distribution agreement for Switzerland withCDP SWISS AG. The sales and marketing effort of SciBase's melanomadetection product Nevisense will initially focus on the nearly 400dermatologists that work in private clinics in Switzerland.

· A change in the Company's board of directors was communicated asViktor Dvrota, as a result of his appointment as Head of Investmentat Karolinska Development, has resigned from SciBase's Board ofDirectors. Alternate director Andreas Pennervall will take his place.

SciBase AB is a Swedish medical technology company, headquartered inStockholm that has developed a unique point-of-care device for theaccurate detection of malignant melanoma. Its product, Nevisense,helps doctors to detect malignant melanoma, the most dangerous typeof skin cancer. SciBase was founded by Stig Ollmar, AssociateProfessor at The Karolinska Institute in Stockholm, Sweden. Nevisenseis based on substantial research and has achieved excellent resultsin the largest clinical study ever conducted on the detection ofmalignant melanoma. Nevisense is CE marked in Europe, has TGAapproval in Australia, and is awaiting FDA clearance in the UnitedStates. Nevisense is based on a method called Electrical ImpedanceSpectroscopy (EIS), which uses the varying electrical properties ofhuman tissue to categorize cellular structures and thereby detectmalignancies. SciBase is listed on Nasdaq First North ("SCIB").Avanza is the certified advisor. Further information is available onwww.scibase.com.

SciBase Holding AB is required to disclose the information providedherein pursuant to the Securities Markets Act and/or the FinancialInstruments Trading Act. The information was submitted forpublication at 8 am on May 13, 2016.